Research progress on intranasal treatment forParkinson'sdisease  

作　　者：Puyuan Wen Chao Ren 

机构地区：[1]Department of Neurology,Yantai Yuhuangding Hospital,Qingdao University,Yantai,Shandong,China [2]Department of Neurology,The First Afliated Hospital of Anhui Medical University,Hefei,Anhui,China [3]Shandong Provincial Clinical Research Centerfor Otorhinolaryngologic Diseases,Yantai Yuhuangding Hospital,Yantai,Shandong,China [4]Yantai Key Laboratory of Otorhinolaryngologic Diseases,Yantai Yuhuangding Hospital,Yantai,Shandong,China [5]Postdoctoral Programme,Yantai Yuhuangding Hospital,Yantai,Shandong,China [6]Department of Otorhinolaryngology,Head and Neck Surgery,Yantai Yuhuangding Hospital,QingdaoUniversity,Yantai,Shandong,China

出　　处：《Neuroprotection》2024年第2期79-99,共21页神经保护（英文）

基　　金：National Natural Science Foundation of China,Grant/AwardNumber:82371119。

摘　　要：Parkinson's disease(PD)is the second most prevalent neurodegenerative disorder globally,significantly affecting the quality of life of affected individuals.Systemic drug delivery to the brain is inefficient because of first-pass metabolism,the blood-brain barrier(BBB),and the blood-cerebrospinal fluid barrier.This inefficiency necessitates increased dosage as the disease progresses,leading to severe side effects that compromise the efficacy of the medication.Nose-to-brain(N2B)administration bypasses the BBB,allowing delivery of both small molecules and large protein substances to the central nervous system.Compared with systemic administration,this method enhances brain bioavailability,reduces enzymatic degradation,and minimizes systemic adverse reactions.However,the N2B delivery system is associated with several critical challenges,including mucociliary clearance,enzymatic degradation,and drug translocation via efflux mechanisms.This paper provides a comprehensive overview of the current research progress in intranasal treatment of PD,considering both preclinical and clinical studies,and discusses the physiological aspects and limitations of its delivery system.

关 键 词：delivery system INTRANASAL nose-to-brain Parkinson's disease TREATMENT 

分 类 号：R742.5[医药卫生—神经病学与精神病学]